"Maker of ALS Drug Considers Market Withdrawal After Failed Clinical Trial"
TL;DR Summary
Amylyx Pharmaceuticals, the maker of the ALS drug Relyvrio, announced that the drug failed to show effectiveness in a large follow-up study and may consider voluntarily withdrawing it from the market. The FDA approved Relyvrio in 2022 despite questionable evidence of its efficacy, and the drug's high price of $158,000 for a year's supply has led to lackluster sales. The company's stock plummeted more than 83% following the announcement.
- Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work Yahoo Finance
- A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market The New York Times
- Amylyx ALS drug fails large clinical trial - STAT STAT
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS Business Wire
- FDA-approved ALS drug Relyvrio could be pulled from market after failing clinical trial USA TODAY
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
87%
535 → 69 words
Want the full story? Read the original article
Read on Yahoo Finance